WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding
Services Inc. (Adelaide, South Australia) for exclusive US rights
to purchase, distribute, and promote Faulding's sustained-release
morphine sulfate product Kadian, an oral medication taken once
or twice daily.
A new drug application (NDA) for use of Kadian in the treatment
of moderate to severe chronic pain is currently under FDA review.
The product is approved and available in Australia and several